SG11201807590SA - Transfected t-cells and t-cell receptors for use in immunotherapy against cancers - Google Patents

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Info

Publication number
SG11201807590SA
SG11201807590SA SG11201807590SA SG11201807590SA SG11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA
Authority
SG
Singapore
Prior art keywords
cells
international
present description
cell receptors
peptides
Prior art date
Application number
SG11201807590SA
Other languages
English (en)
Inventor
Dominik Maurer
Leonie Alten
Sebastian Bunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SG11201807590SA publication Critical patent/SG11201807590SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
SG11201807590SA 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers SG11201807590SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308970P 2016-03-16 2016-03-16
GBGB1604494.3A GB201604494D0 (en) 2016-03-16 2016-03-16 Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
PCT/EP2017/056289 WO2017158116A1 (fr) 2016-03-16 2017-03-16 Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers

Publications (1)

Publication Number Publication Date
SG11201807590SA true SG11201807590SA (en) 2018-10-30

Family

ID=55952419

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807590SA SG11201807590SA (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Country Status (18)

Country Link
US (1) US10537624B2 (fr)
EP (1) EP3430037B1 (fr)
JP (1) JP6929867B2 (fr)
KR (1) KR102266721B1 (fr)
CN (1) CN108884143A (fr)
AU (1) AU2017235069B2 (fr)
BR (1) BR112018067989A2 (fr)
CA (1) CA3017419A1 (fr)
CR (1) CR20180490A (fr)
EA (1) EA201891759A1 (fr)
GB (1) GB201604494D0 (fr)
MA (2) MA43328B2 (fr)
MX (1) MX2018011223A (fr)
PE (1) PE20190124A1 (fr)
SG (1) SG11201807590SA (fr)
TW (1) TWI788284B (fr)
UA (1) UA124532C2 (fr)
WO (1) WO2017158116A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3430037T3 (pl) * 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
US11603519B2 (en) * 2017-02-06 2023-03-14 National Cancer Center Japan T-cell receptor
EP3692063A1 (fr) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Molécules de liaison spécifique à l'hpv
AU2019216982B2 (en) 2018-02-11 2024-07-04 Memorial Sloan-Kettering Cancer Center Non-HLA restricted T cell receptors and uses thereof
CA3090700A1 (fr) 2018-02-12 2019-08-15 Fred Hutchinson Cancer Research Center Recepteurs de lymphocytes t specifiques de la cycline a1 et leurs utilisations
EP3765491B1 (fr) 2018-03-14 2024-04-03 Medigene Immunotherapies GmbH Récepteurs de lymphocyte t inductibles et utilisations associées
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CN112566698A (zh) * 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
US12275773B2 (en) 2018-09-21 2025-04-15 Xlifesc, Ltd. High affinity cell receptor for recognizing AFP antigen
US12179037B2 (en) 2018-12-11 2024-12-31 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
WO2020127827A1 (fr) * 2018-12-20 2020-06-25 Ava Lifescience Gmbh Procédé de sélection d'une molécule biologique de liaison
WO2020191172A1 (fr) 2019-03-19 2020-09-24 Immatics US, Inc. Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
EP3986450A4 (fr) * 2019-06-20 2023-06-28 Memorial Sloan Kettering Cancer Center Récepteurs de lymphocytes t ciblant les mutations pik3ca et leurs utilisations
CN110357953B (zh) * 2019-07-17 2022-05-03 深圳市因诺转化医学研究院 识别人巨细胞病毒pp65抗原的TCR
EP4003375A4 (fr) * 2019-07-31 2023-09-06 Forty Seven, Inc. Régimes d'appauvrissement pour une thérapie à lymphocytes t ou à cellules nk modifiés
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
AU2020344628A1 (en) * 2019-09-12 2022-04-07 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4189074A4 (fr) * 2020-06-22 2025-01-15 Nanjing Legend Biotech Co., Ltd. Lymphocytes t gamma delta t génétquement modifiés pour immunothérapie
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
WO2023044488A1 (fr) 2021-09-20 2023-03-23 Immatics US, Inc. Déplétion monocytaire des populations de lymphocytes t pour une thérapie par lymphocytes t
WO2023081461A1 (fr) 2021-11-08 2023-05-11 Immatics US, Inc. Procédés de génération de sphéroïdes cellulaires
EP4514821A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
EP4514834A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (fr) 2023-11-01 2025-05-08 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
AU2014271235B2 (en) * 2008-10-01 2017-03-02 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
TW201124530A (en) 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
DK2895509T3 (da) * 2012-09-14 2020-03-09 Us Health T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Also Published As

Publication number Publication date
JP6929867B2 (ja) 2021-09-01
CA3017419A1 (fr) 2017-09-21
US10537624B2 (en) 2020-01-21
US20170312350A1 (en) 2017-11-02
TWI788284B (zh) 2023-01-01
CN108884143A (zh) 2018-11-23
AU2017235069B2 (en) 2020-05-07
EP3430037A1 (fr) 2019-01-23
PE20190124A1 (es) 2019-01-17
BR112018067989A2 (pt) 2019-02-05
MA43328A1 (fr) 2019-05-31
UA124532C2 (uk) 2021-10-05
TW201742873A (zh) 2017-12-16
JP2019512242A (ja) 2019-05-16
MX2018011223A (es) 2018-11-22
MA45309B1 (fr) 2023-01-31
KR20180122430A (ko) 2018-11-12
AU2017235069A1 (en) 2018-10-04
KR102266721B1 (ko) 2021-06-17
EA201891759A1 (ru) 2019-02-28
EP3430037B1 (fr) 2022-08-31
CR20180490A (es) 2019-01-10
MA45309A (fr) 2019-01-23
WO2017158116A1 (fr) 2017-09-21
GB201604494D0 (en) 2016-04-27
MA43328B2 (fr) 2022-02-28

Similar Documents

Publication Publication Date Title
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201807300PA (en) Uterine cancer treatments
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201806951TA (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11201806577UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201801670YA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG11201801384YA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201901176XA (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
SG11201801756WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201809781PA (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
SG11201808629UA (en) Immunotherapy against melanoma and other cancers
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201906744VA (en) Core/shell structure platform for immunotherapy
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201908540PA (en) Stable antibody formulation
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs